Ethnic minorities treated with new-generation drug-eluting coronary stents in two European randomised clinical trials.
Coronary artery disease
Drug-eluting stent
Ethnic minority
Percutaneous coronary intervention
Race
Randomised clinical trial
Journal
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
accepted:
11
04
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
22
5
2024
Statut:
aheadofprint
Résumé
Several ethnic minorities have an increased risk of cardiovascular events, but previous European trials that investigated clinical outcome after coronary stenting did not assess the patients' ethnic background. To compare ethnic minority and Western European trial participants in terms of both cardiovascular risk profile and 1‑year clinical outcome after percutaneous coronary intervention. In the BIO-RESORT and BIONYX randomised trials, which assessed new-generation drug-eluting stents, information on patients' self-reported ethnic background was prospectively collected. Pooled patient-level data of 5803 patients, enrolled in the Netherlands and Belgium, were analysed in this prespecified analysis. The main endpoint was target vessel failure after 1 year. Patients were classified as belonging to an ethnic minority (n = 293, 5%) or of Western European origin (n = 5510, 95%). Follow-up data were available in 5772 of 5803 (99.5%) patients. Ethnic minority patients were younger, less often female, more often current smokers, more often medically treated for diabetes, and more often had a positive family history of coronary artery disease. The main endpoint target vessel failure did not differ between ethnic minority and Western European patients (3.5% vs 4.9%, hazard ratio 0.71, 95% confidence interval 0.38-1.33; p = 0.28). There was also no difference in mortality, myocardial infarction, and repeat revascularisation rates. Despite the unfavourable cardiovascular risk profile of ethnic minority patients, short-term clinical outcome after treatment with contemporary drug-eluting stents was highly similar to that in Western European patients. Further efforts should be made to ensure the enrolment of more ethnic minority patients in future coronary stent trials.
Sections du résumé
BACKGROUND
BACKGROUND
Several ethnic minorities have an increased risk of cardiovascular events, but previous European trials that investigated clinical outcome after coronary stenting did not assess the patients' ethnic background.
AIMS
OBJECTIVE
To compare ethnic minority and Western European trial participants in terms of both cardiovascular risk profile and 1‑year clinical outcome after percutaneous coronary intervention.
METHODS
METHODS
In the BIO-RESORT and BIONYX randomised trials, which assessed new-generation drug-eluting stents, information on patients' self-reported ethnic background was prospectively collected. Pooled patient-level data of 5803 patients, enrolled in the Netherlands and Belgium, were analysed in this prespecified analysis. The main endpoint was target vessel failure after 1 year.
RESULTS
RESULTS
Patients were classified as belonging to an ethnic minority (n = 293, 5%) or of Western European origin (n = 5510, 95%). Follow-up data were available in 5772 of 5803 (99.5%) patients. Ethnic minority patients were younger, less often female, more often current smokers, more often medically treated for diabetes, and more often had a positive family history of coronary artery disease. The main endpoint target vessel failure did not differ between ethnic minority and Western European patients (3.5% vs 4.9%, hazard ratio 0.71, 95% confidence interval 0.38-1.33; p = 0.28). There was also no difference in mortality, myocardial infarction, and repeat revascularisation rates.
CONCLUSIONS
CONCLUSIONS
Despite the unfavourable cardiovascular risk profile of ethnic minority patients, short-term clinical outcome after treatment with contemporary drug-eluting stents was highly similar to that in Western European patients. Further efforts should be made to ensure the enrolment of more ethnic minority patients in future coronary stent trials.
Identifiants
pubmed: 38776038
doi: 10.1007/s12471-024-01873-9
pii: 10.1007/s12471-024-01873-9
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Koirala B, Turkson-Ocran RA, Baptiste D, et al. Heterogeneity of cardiovascular disease risk factors among Asian immigrants: insights from the 2010 to 2018 National Health Interview Survey. J Am Heart Assoc. 2021;10:e20408.
doi: 10.1161/JAHA.120.020408
pubmed: 34182790
pmcid: 8403310
Mochari-Greenberger H, Mosca L. Differential outcomes by race and ethnicity in patients with coronary heart disease: a contemporary review. Curr Cardiovasc Risk Rep. 2015;9:20.
doi: 10.1007/s12170-015-0447-4
pubmed: 25914758
pmcid: 4405256
Iantorno M, Torguson R, Kolm P, et al. Relation of sex and race to outcomes in patients undergoing percutaneous intervention with drug-eluting stents. Am J Cardiol. 2019;123:913–8.
doi: 10.1016/j.amjcard.2018.12.021
pubmed: 30595392
Batchelor WB, Ellis SG, Ormiston JA, et al. Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents. J Interv Cardiol. 2013;26:49–57.
doi: 10.1111/j.1540-8183.2012.00760.x
pubmed: 22988961
Chi GC, Kanter MH, Li BH, Qian L, et al. Trends in acute myocardial infarction by race and ethnicity. J Am Heart Assoc. 2020;9:e13542.
doi: 10.1161/JAHA.119.013542
pubmed: 32114888
pmcid: 7335574
Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of older patients, women, and racial/ethnic minority groups in contemporary acute coronary syndrome clinical trials: a systematic review. JAMA Cardiol. 2020;5:714–22.
doi: 10.1001/jamacardio.2020.0359
pubmed: 32211813
Kumar RS, Douglas PS, Peterson ED, et al. Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases. Circulation. 2013;127:1395–403.
doi: 10.1161/CIRCULATIONAHA.113.001437
pubmed: 23547179
Bo A, Zinckernagel L, Krasnik A, Petersen JH, Norredam M. Coronary heart disease incidence among non-Western immigrants compared to Danish-born people: effect of country of birth, migrant status, and income. Eur J Prev Cardiol. 2015;22:1281–9.
doi: 10.1177/2047487314551538
pubmed: 25261269
von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388:2607–17.
doi: 10.1016/S0140-6736(16)31920-1
von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet. 2018;392:1235–45.
doi: 10.1016/S0140-6736(18)32001-4
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.
doi: 10.1161/CIRCULATIONAHA.106.685313
pubmed: 17470709
Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention. 2010;5:871–4.
doi: 10.4244/EIJV5I7A146
pubmed: 20142206
DeVon HA, Burke LA, Nelson H, Zerwic JJ, Riley B. Disparities in patients presenting to the emergency department with potential acute coronary syndrome: it matters if you are Black or White. Heart Lung J Acute Crit Care. 2014;43:270–7
Golomb M, Redfors B, Crowley A, et al. Prognostic impact of race in patients undergoing PCI: analysis from 10 randomized coronary stent trials. JACC Cardiovasc Interv. 2020;13:1586–95.
doi: 10.1016/j.jcin.2020.04.020
pubmed: 32646701
Batchelor W, Kandzari DE, Davis S, et al. Outcomes in women and minorities compared with white men 1 year after everolimus-eluting stent implantation: insights and results from the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study pooled analysis. JAMA Cardiol. 2017;2:1303–13.
doi: 10.1001/jamacardio.2017.3802
pubmed: 29049508
pmcid: 5814993
Abdelnoor M, Eritsland J, Brunborg C, Halvorsen S. Ethnicity and acute myocardial infarction: risk profile at presentation, access to hospital management, and outcome in Norway. Vasc Health Risk Manag. 2012;8:505–15.
doi: 10.2147/VHRM.S33627
pubmed: 22956878
pmcid: 3431960
Moledina SM, Shoaib A, Weston C, et al. Ethnic disparities in care and outcomes of non-ST-segment elevation myocardial infarction: a nationwide cohort study. Eur Heart J Qual Care Clin Outcomes. 2022;8:518–28.
doi: 10.1093/ehjqcco/qcab030
pubmed: 33892502
Ellis SG, Cho L, Raymond R, et al. Comparison of long-term clinical outcomes after drug-eluting stenting in blacks-vs-whites. Am J Cardiol. 2019;124:1179–85.
doi: 10.1016/j.amjcard.2019.07.020
pubmed: 31439280
Rodriguez CJ. Disparities in ideal cardiovascular health: a challenge or an opportunity? Circulation. 2012;125:2963–4.
doi: 10.1161/CIRCULATIONAHA.112.112680
pubmed: 22619285
pmcid: 4433740
Buiten RA, Zocca P, von Birgelen C. Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents. Curr Opin Cardiol. 2020;6:705–11.
doi: 10.1097/HCO.0000000000000786
Kawashima H, Zocca P, Buiten RA, et al. The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective. Neth Heart J. 2020;28:78–87.
doi: 10.1007/s12471-020-01442-w
pubmed: 32780336
pmcid: 7419418
Krackhardt F, Waliszewski M, Ahmad WWA, et al. Polymer-free sirolimus-eluting stent use in Europe and Asia: ethnic differences in demographics and clinical outcomes. PLoS ONE. 2020;15:e226606.
doi: 10.1371/journal.pone.0226606
pubmed: 31929543
pmcid: 6957170
Chandrasekhar J, Kalkman DN, Aquino MB, et al. 1‑year results after PCI with the COMBO stent in all-comers in Asia versus Europe: geographical insights from the COMBO collaboration. Int J Cardiol. 2020;307:17–23.
doi: 10.1016/j.ijcard.2020.01.045
pubmed: 32111358
Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation. 2010;122:1085–90.
doi: 10.1161/CIRCULATIONAHA.109.907998
pubmed: 20805432
Gaglia MA Jr, Shavelle DM, Tun H, et al. African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention. Cardiovasc Revasc Med. 2014;15:214–8.
doi: 10.1016/j.carrev.2014.04.003
pubmed: 24814420
Hannan EL, Racz MJ, Walford G, et al. Disparities in the use of drug-eluting coronary stents by race, ethnicity, payer, and hospital. Can J Cardiol. 2016;32:987:e25–31.
Nørredam M. Migration and health: exploring the role of migrant status through register-based studies. Dan Med J. 2015;62:B5068.
pubmed: 25872539
Gaglia MA Jr, Steinberg DH, Slottow PTL, et al. Racial disparities in outcomes following percutaneous coronary intervention with drug-eluting stents. Am J Cardiol. 2009;103:653–8.
doi: 10.1016/j.amjcard.2008.10.043
pubmed: 19231328